Innovator’s Pitch Challenge
Remedium is a gene therapy company developing therapeutics for the treatment of diseases that comprise large unmet clinical needs. The company’s lead candidate, RMD1101, is a single injection gene therapy potentially capable of reversing cartilage loss in Osteoarthritis (OA), that is being studied in a research collaboration with Tufts University. In vivo data data demonstrate the significant advantages of the company’s proprietary approach. RMD1101 will be developed for human and animal markets. Remedium’s pipeline includes potential treatments for the management of Type 2 Diabetes and Ischemic Stroke, as well as a platform technology to enable dose up- and down-titration of the gene therapy following initial administration.
Contact Us:
Frank Luppino
fluppino@remedium-bio.com